What we're reading, February 23, 2016: drug spending for CVS health plans slowed from 11.8% to 5%; CDC Director Tom Frieden, MD, MPH, talks Zika virus; and an investigation into the HealthCare.gov launch found widespread mismanagement.
Drug spending growth slowed from 11.8% in 2014 to 5% in 2015, according to CVS Health Corp. In an interview with Bloomberg Business, the company’s chief medical officer, Troyen Brennan, explained that the company kept costs down through discount negotiations and restrictions on some high-priced drugs. As a result, even though more patients were using expensive hepatitis C drugs, spending on these treatments was roughly flat over the course of the year.
In a conversation with Time, CDC Director Tom Frieden, MD, MPH, explained that researchers continue to see a strong connection between the Zika virus and microcephaly, but no definitive proof yet. In addition, he added that the CDC expects to see hundreds, if not thousands, of travel-associated Zika cases in the US. There are already 84 travel-associated reported cases, plus more than 2 dozen locally transmitted cases reported in Puerto Rico and more cases in the US Virgin Islands and American Samoa.
A 2-year inquiry into the failings of the HealthCare.gov launch found that federal officials received 18 warnings that the project was mismanaged and never considered postponing the launch. An outside consultant gave 11 reviews that included a list of risks citing inadequate planning for capacity and deviations from usual information technology standards, reported The Washington Post.
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials
January 9th 2025Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Read More
New Research Links Gender, Racial Microaggressions to Higher Postpartum Blood Pressure
January 9th 2025Acts of discrimination, including subtle microaggressions, during pregnancy and childbirth contribute to higher maternal mortality rates, especially among Black women, and are linked to increased postpartum blood pressure, highlighting the need for improved health care interventions and racial equity in maternity care.
Read More